Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer

被引：13
作者：
Galland, Loick [1 ,2 ,3 ]
Lecuelle, Julie [1 ,3 ]
Favier, Laure [1 ,3 ]
Fraisse, Clea [3 ]
Lagrange, Aurelie [3 ]
Kaderbhai, Coureche [3 ]
Truntzer, Caroline [1 ,4 ,5 ]
Ghiringhelli, Francois [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Georges Francois Leclerc Canc Ctr UNICANCER, Platform Transfer Biol Oncol, F-21000 Dijon, France
[2] Univ Burgundy Franche Comte, Maison Univ Esplanade Erasme, F-21000 Dijon, France
[3] Georges Francois Leclerc Canc Ctr UNICANCER, Dept Med Oncol, F-21000 Dijon, France
[4] Dijon Univ Hosp, Genom & Immunotherapy Med Inst, F-21000 Dijon, France
[5] UMR INSERM 1231, F-21000 Dijon, France
来源：
CANCERS | 2021年 / 13卷 / 12期
关键词：
lung cancer; immunotherapy; splenomegaly; prognostic biomarkers; TO-LYMPHOCYTE RATIO; SUPPRESSOR-CELLS; BASE-LINE; PEMBROLIZUMAB; ASSOCIATION; OUTCOMES;
D O I：
10.3390/cancers13123020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Simple Summary Monoclonal antibodies targeting PD1/PD-L1 are game changers in the treatment of advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported the prognostic role of splenic volume in digestive cancer and its correlation with the presence of immunosuppressive cells. The aim of this study was to evaluate the prognostic role of splenic volume in NSCLC patients treated with immune checkpoint inhibitors (ICIs). Monoclonal antibodies targeting PD1/PD-L1 are game changers in advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported the prognostic role of splenic volume in digestive cancer and its correlation with the presence of immunosuppressive cells. The aim of this study was to evaluate the prognostic role of splenic volume in NSCLC patients treated with immune checkpoint inhibitors (ICIs). We conducted a retrospective study of 276 patients receiving ICIs for advanced NSCLC in the Georges Francois Leclerc Cancer Center. The association between splenic volume at baseline and at two months of therapy and progression-free survival (PFS) during ICI treatment or overall survival (OS) from ICI initiation was evaluated using univariate and multivariable Cox analyses. Splenic volume during treatment and the change in splenic volume were associated with poor PFS (respectively p = 0.02 and p = 0.001) and with OS (respectively p < 1.10(-3) and p < 1.10(-3)). Baseline splenic volume at the first evaluation was also associated with poor OS (p = 0.001). LDH rate and dNLR were positively correlated with splenic volume, as well as with its evolution. After the adjustment of clinical variables, splenic volumes remained a predictive marker of immunotherapy efficacy. Splenic volume is a prognostic biomarker in patients with advanced NSCLC treated with ICIs.
引用
收藏
页数：13
相关论文
共 36 条
[1]  
Aarnink Anne, 2018, Oncotarget, V9, P25617, DOI 10.18632/oncotarget.25424
[2]   Lung Cancer 2020 Epidemiology, Etiology, and Prevention [J].
Bade, Brett C. ;
Dela Cruz, Charles S. .
CLINICS IN CHEST MEDICINE, 2020, 41 (01) :1-+
[3]   Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].
Bagley, Stephen J. ;
Kothari, Shawn ;
Aggarwal, Charu ;
Bauml, Joshua M. ;
Alley, Evan W. ;
Evans, Tracey L. ;
Kosteva, John A. ;
Ciunci, Christine A. ;
Gabriel, Peter E. ;
Thompson, Jeffrey C. ;
Stonehouse-Lee, Susan ;
Sherry, Victoria E. ;
Gilbert, Elizabeth ;
Eaby-Sandy, Beth ;
Mutale, Faith ;
DiLullo, Gloria ;
Cohen, Roger B. ;
Vachani, Anil ;
Langer, Corey J. .
LUNG CANCER, 2017, 106 :1-7
[4]   Near-optimal probabilistic RNA-seq quantification [J].
Bray, Nicolas L. ;
Pimentel, Harold ;
Melsted, Pall ;
Pachter, Lior .
NATURE BIOTECHNOLOGY, 2016, 34 (05) :525-527
[5]   The Spleen in Local and Systemic Regulation of Immunity [J].
Bronte, Vincenzo ;
Pittet, Mikael J. .
IMMUNITY, 2013, 39 (05) :806-818
[6]   Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma [J].
Chen, Yang ;
Yan, Huan ;
Wang, YanRong ;
Shi, Yan ;
Dai, GuangHai .
SCIENTIFIC REPORTS, 2017, 7
[7]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[8]   Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab [J].
Ferrucci, P. F. ;
Ascierto, P. A. ;
Pigozzo, J. ;
Del Vecchio, M. ;
Maio, M. ;
Cappellini, G. C. Antonini ;
Guidoboni, M. ;
Queirolo, P. ;
Savoia, P. ;
Mandala, M. ;
Simeone, E. ;
Valpione, S. ;
Altomonte, M. ;
Spagnolo, F. ;
Cocorocchio, E. ;
Gandini, S. ;
Giannarelli, D. ;
Martinoli, C. .
ANNALS OF ONCOLOGY, 2016, 27 (04) :732-738
[9]   Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 [J].
Gabitass, Rachel F. ;
Annels, Nicola E. ;
Stocken, Deborah D. ;
Pandha, Hardev A. ;
Middleton, Gary W. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (10) :1419-1430
[10]   Myeloid-Derived Suppressor Cells [J].
Gabrilovich, Dmitry I. .
CANCER IMMUNOLOGY RESEARCH, 2017, 5 (01) :3-8
1234